{"id":"chloroquine","rwe":[{"pmid":"41901254","year":"2026","title":"Captivating Synergistic, Dose-Dependent Anticancer Effects of Tumor-Regulation Modulators Chloroquine and Ivermectin Completely Abolished by an Opposing Modulator, Deoxycholic Acid, in Hamster Fibrosarcoma: In Vivo, In Vitro, and Literature Review.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41899507","year":"2026","title":"Triptolide Triggers Protective Autophagy via ROS Induction in NSCLC: Therapeutic Synergy with Autophagy Inhibition.","finding":"","journal":"Cancers","studyType":"Clinical Study"},{"pmid":"41894411","year":"2026","title":"Reduced cytochrome P-450 (CYP) 2D6 activity and Plasmodium vivax malaria risk in Amazonians: A retrospective, population-based cohort study.","finding":"","journal":"PLoS neglected tropical diseases","studyType":"Clinical Study"},{"pmid":"41891011","year":"2026","title":"Sustained High Prevalence of Multiple Antimalarial Drug Resistance Markers in Uganda in 2023-24.","finding":"","journal":"medRxiv : the preprint server for health sciences","studyType":"Clinical Study"},{"pmid":"41886893","year":"2026","title":"Restoration of autophagy-lysosomal function via transcranial focused ultrasound stimulation ameliorates β-amyloid pathology and cognitive deficits in an Alzheimer's disease model.","finding":"","journal":"Ultrasonics","studyType":"Clinical Study"}],"_fda":{"id":"6d4407d6-9669-4bf6-91cf-05ec2d70c96a","set_id":"06c69e2b-211b-4746-9f3a-f86d36520570","openfda":{"upc":["0364980178020"],"unii":["6E17K3343P"],"route":["ORAL"],"rxcui":["1116758"],"spl_id":["6d4407d6-9669-4bf6-91cf-05ec2d70c96a"],"brand_name":["Chloroquine Phosphate"],"spl_set_id":["06c69e2b-211b-4746-9f3a-f86d36520570"],"package_ndc":["64980-178-02","64980-178-01","64980-178-05","64980-178-10"],"product_ndc":["64980-178"],"generic_name":["CHLOROQUINE PHOSPHATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CHLOROQUINE PHOSPHATE"],"manufacturer_name":["Rising Pharma Holdings, Inc."],"application_number":["ANDA090612"],"is_original_packager":[true]},"version":"6","warnings":["WARNINGS Chloroquine-Resistant Malaria Chloroquine phosphate tablets are not effective against chloroquine-or hydroxychloroquine-resistant strains of Plasmodium species (see CLINICAL PHARMACOLOGY , Microbiology ). Chloroquine resistance is widespread in P. falciparum and is reported in P. vivax . Before using chloroquine for prophylaxis, it should be ascertained whether chloroquine is appropriate for use in the region to be visited by the traveler. Information regarding the geographic areas where resistance to chloroquine occurs, is available at the Centers for Disease Control and Prevention (www.cdc.gov\\malaria). Patients infected with a resistant strain of plasmodia as shown by the fact that normally adequate doses have failed to prevent or cure clinical malaria or parasitemia should be treated with another form of antimalarial therapy. Treatment of Exo-Erythocytic Forms of Malaria Chloroquine does not treat the hypnozoite liver stage forms of Plasmodium and will therefore not prevent relapses of malaria due to P. vivax or P. ovale . Additional treatment with an anti-malarial agent active against these forms, such as an 8-aminoquinoline, is required for the treatment of infections with P. vivax and P. ovale . Cardiac Effects including Cardiomyopathy and QT prolongation Fatal and life-threatening cardiotoxicity, including cardiomyopathy and arrhythmias, have been reported with the use of chloroquine (see ADVERSE REACTIONS and OVERDOSAGE ). In multiple cases, endomyocardial biopsy showed association of the cardiomyopathy with phospholipidosis in the absence of inflammation, infiltration or necrosis. Patients may present with ventricular hypertrophy and conduction disorders. ECG findings include atrioventircular, right or left bundle branch block. Chronic toxicity should be considered when conduction disorders (bundle branch block/ atrio-ventricular heart block) are diagnosed. QT interval proongation, torsades de pointes, and ventricular arrhythmias have been reported with the use of chloroquine. The risk is greater if chloroquine is administered at high doses. Chloroquine should be used with caution in patients with cardiac disease,a history of ventricular arrhythmias, uncorrected hypokalemia and/or hypomagnesemia, or bradycardia (< 50bpm), and during concomitant administration with QT interval prolonging agents due to potential for QT interval prolongation (see WARNINGS , PRECAUTIONS , Drug Interactions, ADVERSE REACTIONS and OVERDOSAGE ) Monitor for signs and symptoms of cardiotoxicity is suspected or demonstrated by tissue biopsy. Skeletal Muscle Myopathy and Neuropathy Skeletal muscle myopathy and neuropathy leading to progressive weakness and atrophy of proximal muscle groups, and abnormal nerve conduction, have been reported. Muscle and nerve biopsies have shown associated phospholipidosis. Assess muscle strength and deep tendon reflexes periodically in patients on long-term therapy with chloroquine. Discontinue chloroquine if muscle or nerve toxicity is suspected or demonstrated by tissue biopsy. Hypoglycemia Chloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life-threatening in patients treated with or without antidiabetic medications (see PRECAUTIONS , Drug Interactions). Patients treated with chloroquine phosphate tablets should be warned about the risk of hypoglycemia and the associated clinical signs and symptoms. Patients presenting with clinical symptoms suggestive of hypoglycemia during treatment with chloroquine should have their blood glucose level checked and treatment reviewed as necessary. Retinopathy 1 Irreversible retinal damage has been observed in some patients who had received chloroquine. Significant risk factors for retinal damage include daily doses of chloroquine phosphate greater than 2.3 mg/kg of actual body weight, durations of use greater than five years, subnormal glomerular filtration, use of some concomitant drug products such as tamoxifen citrate (see PRECAUTIONS ), and concurrent macular disease. A baseline ophthalmological examination should be performed within the first year of starting chloroquine phosphate tablets. The baseline exam should include: best corrected distance visual acuity (BCVA), an automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and spectral domain optical coherence tomography (SD-OCT). For individuals with significant risk factors (daily dose of chloroquine phosphate greater than 2.3 mg/kg of actual body weight, subnormal glomerular filtration, use of tamoxifen citrate or concurrent macular disease) monitoring should include annual examinations which include BCVA, VF and SDOCT. For individuals without significant risk factors, annual exams (including BCVA, VF and SD-OCT) can usually be deferred until five years of treatment. In individuals of Asian descent, retinal toxicity may first be noticed outside the macula. In patients of Asian descent, it is recommended that visual field testing be performed in the central 24 degrees instead of the central 10 degrees. It is recommended that chloroquine be discontinued if ocular toxicity is suspected and the patient should be closely observed given that retinal changes (and visual disturbances) may progress even after cessation of therapy. Central Nervous System Effects Acute extrapyramidal disorders may occur with chloroquine (see PRECAUTIONS , ADVERSE REACTIONS and OVERDOSAGE ). These adverse reactions usually resolve after treatment discontinuation and/or symptomatic treatment. Renal Toxicity Proteinuria with or without a moderate reduction in glomerular filteration rate have been reported with the use of chloroquine. Renal biopsy showed phospholipidosis without immune deposits, inflammation, and/or increased cellularity. Physcians should consider phospholipidosis as a possible cause of renal injury in patients with underlying connective tissue disorders who are receiving chloroquine. Discontinue chloroquine if renal toxicity is suspected or demonstrated by tissue biopsy. Pediatric Accidental Ingestion A number of fatalities have been reported following the accidental ingestion of chloroquine, sometimes in relatively small doses (0.75 g or 1 g chloroquine phosphate in one 3-year-old child). Patients should be strongly warned to keep chloroquine phosphate tablets out of the reach of children because they are especially sensitive to the 4-aminoquinoline compounds (see OVERDOSAGE and ADVERSE REACTIONS ). Worsening of Psoriasis and Porphyria Use of chloroquine phosphate tablets in patients with psoriasis may precipitate a severe attack of psoriasis. When used in patients with porphyria the condition may be exacerbated. Chloroquine phosphate tablets should not be used in these conditions unless the benefit to the patient outweighs the potential risks. Potential Carcinogenic Risk Experimental data showed a potential risk of inducing gene mutations. There is insufficient evidence regarding the carcinogenecity of chloroquine in experimental animals (see PRECAUTIONS , Carcinogenesis, Mutagenesis, Impairment of Fertility). In humans, there are insufficient data to rule out an increased risk of cancer in patients receiving long-term treatment. Usage in Pregnancy In animal studies, embryo-fetal developmental toxicity was shown at doses ranging from 250 to 1500 mg/kg body weight; approximately 3 to 16 times the maximum recommended therapeutic dose based on a body surface area comparison (see PRECAUTIONS , Animal Pharmacology and/or Animal Toxicology). Preclinical data showed a potential risk of genotoxicity in some test systems ( PRECAUTIONS , Carcinogenesis, Mutagenesis, Impairment of Fertility). In humans, at recommended doses for prophylaxis and treatment of malaria, observational studies as well as a meta-analysis, including a small number of prospective studies with chloroquine exposure during pregnancy, have shown no increase in the rate of birth defects or spontaneous abortions. The individual benefit-risk balance should be reviewed before prescribing chloroquine in pregnant women."],"overdosage":["OVERDOSAGE Signs and Symptoms: Chloroquine is very rapidly and completely absorbed after ingestion. Toxic doses of chloroquine can be fatal. As little as 1 g may be fatal in children. Toxic symptoms can occur within minutes. The symptoms of overdosage may include nausea, vomiting, headache, drowsiness, visual disturbances, cardiovascular collapse, convulsions, hypokalemia, rhythm and conduction disorders including QT prolongation, torsades de pointes, ventricular tachycardia and ventricular fibrillation, followed by sudden potentially fatal respiratory and cardiac arrest. Immediate medical attention is required, as these effects may appear shortly after the overdose. Cases of extrapyramidal disorders have also been reported in the context of chloroquine overdose (see WARNINGS and ADVERSE REACTIONS ). Treatment: Treatment is symptomatic and must be prompt with immediate evacuation of the stomach by emesis or gastric lavage followed by treatment with activated charcoal. Chloroquine overdose is a life-threatening emergency and should be managed with cardio-respiratory and hemodynamic support, monitoring of potassium along with management of arrhythmias and convulsions, as necessary. A patient who survives the acute phase and is asymptomatic should be closely observed until all clinical features of toxicity resolve."],"references":["REFERENCES Marmor MF, Kellner U, and Lai TY, et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology 2016. Doi10.1016./jophtha.2016.01.058 Rx Only Manufactured by: Natco Pharma Limited Visakhapatnam-531019 AP, India Distributed by: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816 Revised: 08/2024"],"description":["DESCRIPTION Chloroquine phosphate tablets, USP, is a 4-aminoquinoline compound for oral administration. It is a white, odorless, bitter tasting, crystalline substance, freely soluble in water. Chloroquine phosphate tablets are an antimalarial and amebicidal drug. Chemically, it is 7-chloro-4-[[4-(diethylamino)-1-methylbutyl]amino]quinoline phosphate (1:2) andhas the following structural formula: Each tablet contains 500 mg of chloroquine phosphate USP, equivalent to 300 mg chloroquine base. Inactive Ingredients: Colloidal silicon dioxide, dibasic calcium phosphate, magnesium stearate, microcrystalline cellulose, pregelatinized starch and sodium starch glycolate. The coating material contains hypromellose, polyethylene glycol, polysorbate 80 and titanium dioxide. Structural Formula"],"precautions":["PRECAUTIONS Hematological Effects/Laboratory Tests Complete blood cell counts should be checked periodically if patients are given prolonged therapy (see ADVERSE REACTIONS ). Chloroquine may cause hemolysis in glucose-6 phosphate dehydrogenase (G-6-PD) deficiency. Blood monitoring may be needed as hemolytic anemia may occur, in particular in association with other drugs that cause hemolysis (see ADVERSE REACTIONS ). Auditory Effects In patients with preexisting auditory damage, chloroquine should be administered with caution. In case of any defects in hearing, chloroquine should be immediately discontinued, and the patient closely observed (see ADVERSE REACTIONS ). Use in Patients with Hepatic Impairment Since chloroquine phosphate tablets are known to concentrate in the liver, it should be used with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs. Central Nervous System Effects Chloroquine may increase the risk of convulsions in patients with a history of epilepsy. Drug Interactions Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine; an interval of at least 4 hours between intake of these agents and chloroquine should be observed. Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level. Concomitant use of cimetidine should be avoided. Insulin and other antidiabetic drugs: As chloroquine may enhance the effects of a hypoglycemic treatment, a decrease in doses of insulin or other antidiabetic drugs may be required. Arrhythmogenic drugs: There may be an increased risk of inducing ventricular arrhythmias if chloroquine is used concomitantly with other arrhythmogenic drugs, such as amiodarone or moxifloxacin. Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin. An interval of at least two hours between intake of ampicillin and chloroquine should be observed. Cyclosporine: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporine level has been reported. Therefore, close monitoring of serum cyclosporine level is recommended and, if necessary, chloroquine should be discontinued. Mefloquine: Co-administration of chloroquine and mefloquine may increase the risk of convulsions. The blood concentrations of chloroquine and desethylchloroquine (the major metabolite of chloroquine, which also has antimalarial properties) were negatively associated with log antibody titers. Chloroquine taken in the dose recommended for malaria prophylaxis can reduce the antibody response to primary immunization with intradermal human diploid-cell rabies vaccine. Praziquantel: In a single-dose interaction study, chloroquine has been reported to reduce the bioavailability of praziquantel. Tamoxifen: Concomitant use of chloroquine with drugs known to induce retinal toxicity such as tamoxifen is not recommended (see WARNINGS ). Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis There is insufficient evidence regarding the carcinogenicity of chloroquine in experimental animals. Mutagenesis Chloroquine is reported in the literature to be a weak genotoxic agent which may elicit both gene mutations and chromosomal/DNA breaks. Mechanisms may involve DNA intercalation or induction of oxidative stress. The publications reported both positive and negative results in the in vitro reverse gene mutation assays using bacteria (Ames test) and in the in vivo studies using rodents (mouse bone marrow cell sister chromatid exchange, mouse bone marrow cell chromosome abnormality, and rat DNA strand breaks in multiple organs when animals were dosed by intraperitoneal route). Those chromosomal effects were not observed when chloroquine was administered in animals orally (i.e. the therapeutic route of administration). Altogether those cellular and rodent data show evidence of genotoxic potential but discrepancies have been noted between published data. Fertility A study in male rats after 30 days of oral treatment at 5 mg/day of chloroquine showed a decrease in testosterone levels, weight of testes, epididymis, seminal vesicles, and prostate. Untreated female rats had reduced number of fetuses after mating with males that received intraperitoneal injections of 10 mg/kg chloroquine for 14 days. Animal Pharmacology and/or Animal Toxicology Based on non-Good Laboratory Practice literature reports, chloroquine causes malformations in rats, resulting in a fetal mortality rate of 25% after administration at doses between 250 and 1500 mg/kg (approximately 3 to 16 times the maximum recommended therapeutic dose of 900 mg of chloroquine base, based on a body surface area comparison), showing ocular malformations in 45% of fetuses in the 1000 mg/kg group (approximately 11 times the maximum recommended therapeutic dose based on a body surface area comparison). Autoradiographic studies have shown that when administered at the start or the end of gestation, chloroquine accumulates in the eyes and ears. Pregnancy See WARNINGS, Usage in Pregnancy. Nursing Mothers Because of the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the potential clinical benefit of the drug to the mother. The excretion of chloroquine and the major metabolite, desethylchloroquine, in breast milk wasinvestigated in eleven lactating mothers following a single oral dose of chloroquine (600 mg base). The maximum daily dose of the drug that the infant can receive from breastfeeding was about 0.7% of the maternal start dose of the drug in malaria chemotherapy. Separate chemoprophylaxis for the infant is required (see DOSAGE AND ADMINISTRATION ). Pediatric Use See WARNINGS and DOSAGE AND ADMINISTRATION. Geriatric Use Clinical studies of Chloroquine phosphate tablets did not include sufficient numbers of subjects aged 65and over to determine whether they respond differently from younger subjects. However, this drugis known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug maybe greater in patients with impaired renal function. Because elderly patients are more likely to havedecreased renal function, care should be taken in dose selection and it may be useful to monitorrenal function.","Hematological Effects/Laboratory Tests Complete blood cell counts should be checked periodically if patients are given prolonged therapy (see ADVERSE REACTIONS ). Chloroquine may cause hemolysis in glucose-6 phosphate dehydrogenase (G-6-PD) deficiency. Blood monitoring may be needed as hemolytic anemia may occur, in particular in association with other drugs that cause hemolysis (see ADVERSE REACTIONS ).","Auditory Effects In patients with preexisting auditory damage, chloroquine should be administered with caution. In case of any defects in hearing, chloroquine should be immediately discontinued, and the patient closely observed (see ADVERSE REACTIONS ).","Use in Patients with Hepatic Impairment Since chloroquine phosphate tablets are known to concentrate in the liver, it should be used with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs.","Central Nervous System Effects Chloroquine may increase the risk of convulsions in patients with a history of epilepsy.","Drug Interactions Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine; an interval of at least 4 hours between intake of these agents and chloroquine should be observed. Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level. Concomitant use of cimetidine should be avoided. Insulin and other antidiabetic drugs: As chloroquine may enhance the effects of a hypoglycemic treatment, a decrease in doses of insulin or other antidiabetic drugs may be required. Arrhythmogenic drugs: There may be an increased risk of inducing ventricular arrhythmias if chloroquine is used concomitantly with other arrhythmogenic drugs, such as amiodarone or moxifloxacin. Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin. An interval of at least two hours between intake of ampicillin and chloroquine should be observed. Cyclosporine: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporine level has been reported. Therefore, close monitoring of serum cyclosporine level is recommended and, if necessary, chloroquine should be discontinued. Mefloquine: Co-administration of chloroquine and mefloquine may increase the risk of convulsions. The blood concentrations of chloroquine and desethylchloroquine (the major metabolite of chloroquine, which also has antimalarial properties) were negatively associated with log antibody titers. Chloroquine taken in the dose recommended for malaria prophylaxis can reduce the antibody response to primary immunization with intradermal human diploid-cell rabies vaccine. Praziquantel: In a single-dose interaction study, chloroquine has been reported to reduce the bioavailability of praziquantel. Tamoxifen: Concomitant use of chloroquine with drugs known to induce retinal toxicity such as tamoxifen is not recommended (see WARNINGS ). Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis There is insufficient evidence regarding the carcinogenicity of chloroquine in experimental animals. Mutagenesis Chloroquine is reported in the literature to be a weak genotoxic agent which may elicit both gene mutations and chromosomal/DNA breaks. Mechanisms may involve DNA intercalation or induction of oxidative stress. The publications reported both positive and negative results in the in vitro reverse gene mutation assays using bacteria (Ames test) and in the in vivo studies using rodents (mouse bone marrow cell sister chromatid exchange, mouse bone marrow cell chromosome abnormality, and rat DNA strand breaks in multiple organs when animals were dosed by intraperitoneal route). Those chromosomal effects were not observed when chloroquine was administered in animals orally (i.e. the therapeutic route of administration). Altogether those cellular and rodent data show evidence of genotoxic potential but discrepancies have been noted between published data. Fertility A study in male rats after 30 days of oral treatment at 5 mg/day of chloroquine showed a decrease in testosterone levels, weight of testes, epididymis, seminal vesicles, and prostate. Untreated female rats had reduced number of fetuses after mating with males that received intraperitoneal injections of 10 mg/kg chloroquine for 14 days. Animal Pharmacology and/or Animal Toxicology Based on non-Good Laboratory Practice literature reports, chloroquine causes malformations in rats, resulting in a fetal mortality rate of 25% after administration at doses between 250 and 1500 mg/kg (approximately 3 to 16 times the maximum recommended therapeutic dose of 900 mg of chloroquine base, based on a body surface area comparison), showing ocular malformations in 45% of fetuses in the 1000 mg/kg group (approximately 11 times the maximum recommended therapeutic dose based on a body surface area comparison). Autoradiographic studies have shown that when administered at the start or the end of gestation, chloroquine accumulates in the eyes and ears.","Pregnancy See WARNINGS, Usage in Pregnancy.","Nursing Mothers Because of the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the potential clinical benefit of the drug to the mother. The excretion of chloroquine and the major metabolite, desethylchloroquine, in breast milk wasinvestigated in eleven lactating mothers following a single oral dose of chloroquine (600 mg base). The maximum daily dose of the drug that the infant can receive from breastfeeding was about 0.7% of the maternal start dose of the drug in malaria chemotherapy. Separate chemoprophylaxis for the infant is required (see DOSAGE AND ADMINISTRATION ).","Pediatric Use See WARNINGS and DOSAGE AND ADMINISTRATION.","Geriatric Use Clinical studies of Chloroquine phosphate tablets did not include sufficient numbers of subjects aged 65and over to determine whether they respond differently from younger subjects. However, this drugis known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug maybe greater in patients with impaired renal function. Because elderly patients are more likely to havedecreased renal function, care should be taken in dose selection and it may be useful to monitorrenal function."],"how_supplied":["HOW SUPPLIED Tablets containing 500 mg chloroquine phosphate USP, equivalent to 300 mg of chloroquine base Bottle of 25 (NDC 64980-178-02) Bottle of 100 (NDC 64980-178-01) Bottle of 500 (NDC 64980-178-05) Bottle of 1000 (NDC 64980-178-10) White, round, biconvex film-coated tablets, with debossing of ‘CN 500’ on one side and plain surface on the other side. Dispense in tight, light-resistant container as defined in the USP/NF. Store at 20-25° C (68-77° F); excursions permitted to 15° – 30° C (59° – 86° F) [See USP Controlled Room Temperature]"],"microbiology":["Microbiology Mechanism of Action: Chloroquine, a 4-aminoquinoline, is an anti-protozoal agent. The precise mechanism by which chloroquine exhibits activity is not known. Chloroquine, may exert its effect against Plasmodium species by concentrating in the acid vesicles of the parasite and by inhibiting polymerization of heme. It can also inhibit certain enzymes by its interaction with DNA. Activity in Vitro and in Clinical Infections: Chloroquine is active against the erythrocytic forms of susceptible strains of Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale , and Plasmodium vivax . Chloroquine is not active against the gametocytes and the exoerythrocytic forms including the hypnozoite stage ( P. vivax and P. ovale ) of the Plasmodium parasites. In vitro studies with Chloroquine demonstrated that it is active against the trophozoites of Entamoeba histolytica. Drug Resistance: Resistance of Plasmodium parasites to chloroquine is widespread (see INDICATIONS AND USAGE , Limitations of Use in Malaria and WARNINGS ). Plasmodium parasites exhibiting reduced susceptibility to hydroxychloroquine also show reduced susceptibility to chloroquine. Patients in whom chloroquine or hydroxychloroquine have failed to prevent or cure clinical malaria or parasitemia, or patients who acquired malaria in a geographic area where chloroquine resistance is known to occur should be treated with another form of antimalarial therapy (see WARNINGS and INDICATIONS AND USAGE , Limitations of Use)."],"effective_time":"20241001","adverse_reactions":["ADVERSE REACTIONS The following adverse reactions have been identified during post-approval use of chloroquine or other 4-aminoqunoline compounds. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Ocular disorders: Maculopathy and macular degeneration have been reported and may be irreversible. Irreversible retinopathy with retinal pigmentation changes (bull’s eye appearance) and visual field defects (paracentral scotomas) in patients receiving long-term or high-dosage 4-aminoquinoline therapy have been reported (see WARNINGS ). Visual disturbances (blurring of vision and difficulty of focusing or accommodation); nyctalopia; scotomatous vision with field defects of paracentral, pericentral ring types, and typically temporal scotomas (e.g., difficulty in reading with words tending to disappear, seeing half an object, misty vision, and fog before the eyes) have been reported. Reversible corneal opacities have also been reported. Immune system disorders: Urticaria, anaphylactic reaction including angioedema. Ear and labyrinth disorders: Nerve type deafness; tinnitus, reduced hearing in patients with preexisting auditory damage. Musculoskeletal and connective tissue-disorders : Sensorimotor disorders, skeletal muscle myopathy or neuromyopathy leading to progressive weakness and atrophy of proximal muscle groups, depression of tendon reflexes and abnormal nerve conduction. Gastrointestinal disorders: Hepatitis, increased liver enzymes, anorexia, nausea, vomiting, diarrhea, abdominal cramps. Skin and subcutaneous tissue disorders: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis. Pleomorphic skin eruptions, skin and mucosal pigmentary changes; lichen planus-like eruptions, pruritus,; drug rash with eosinophilia and systemic symptoms (DRESS syndrome); photosensitivity and hair loss and bleaching of hair pigment. Blood and lymphatic system disorders: Pancytopenia, aplastic anemia, reversible agranulocytosis, thrombocytopenia and neutropenia. Hemolytic anemia in G6PD deficient patients (see PRECAUTIONS ). Nervous system disorders: Convulsions, mild and transient headache, polyneuropathy, acute extrapyramidal disorders (such as dystonia, dyskinesia, tongue protrusion, torticollis) (see WARNINGS and OVERDOSAGE ). Neuropsychiatric disorders: Neuropsychiatric changes including psychosis, delirium, anxiety, agitation, insomnia, confusion, hallucinations, personality changes, depression, and suicidal behavior. Cardiac disorders: Hypotension, electrocardiographic changes (particularly, inversion or depression of the T-wave with widening of the QRS complex), and cardiomyopathy (which may result in cardiac failure and in some cases a fatal outcome). Cardiac arrhythmias, conduction disorders such as bundle branch block / atrio-ventricular block, QT interval prolongation, torsade de pointes, ventricular tachycardia and ventricular fibrillation have been reported with therapeutic doses of chloroquine as well as with overdose. The risk is greater if chloroquine is administered at high doses. Fatal cases have been reported (see WARNINGS , Cardiac Effects and OVERDOSAGE ). Metabolic and Nutritional disorders: Hypoglycemia (see WARNINGS )."],"contraindications":["CONTRAINDICATIONS Use of chloroquine phosphate tablets for indications other than acute malaria is contraindicated in the presence of retinal or visual field changes of any etiology. Use of chloroquine phosphate tablets is contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds."],"mechanism_of_action":["Mechanism of Action: Chloroquine, a 4-aminoquinoline, is an anti-protozoal agent. The precise mechanism by which chloroquine exhibits activity is not known. Chloroquine, may exert its effect against Plasmodium species by concentrating in the acid vesicles of the parasite and by inhibiting polymerization of heme. It can also inhibit certain enzymes by its interaction with DNA. Activity in Vitro and in Clinical Infections: Chloroquine is active against the erythrocytic forms of susceptible strains of Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale , and Plasmodium vivax . Chloroquine is not active against the gametocytes and the exoerythrocytic forms including the hypnozoite stage ( P. vivax and P. ovale ) of the Plasmodium parasites. In vitro studies with Chloroquine demonstrated that it is active against the trophozoites of Entamoeba histolytica. Drug Resistance: Resistance of Plasmodium parasites to chloroquine is widespread (see INDICATIONS AND USAGE , Limitations of Use in Malaria and WARNINGS ). Plasmodium parasites exhibiting reduced susceptibility to hydroxychloroquine also show reduced susceptibility to chloroquine. Patients in whom chloroquine or hydroxychloroquine have failed to prevent or cure clinical malaria or parasitemia, or patients who acquired malaria in a geographic area where chloroquine resistance is known to occur should be treated with another form of antimalarial therapy (see WARNINGS and INDICATIONS AND USAGE , Limitations of Use)."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Chloroquine is rapidly and almost completely absorbed from the gastrointestinal tract, and only a small proportion of the administered dose is found in the stools. Approximately 55% of the drug in the plasma is bound to nondiffusible plasma constituents. Excretion of chloroquine is quite slow,but is increased by acidification of the urine. Chloroquine is deposited in the tissues in considerable amounts. In animals, from 200 to 700 times the plasma concentration may be found in the liver,spleen, kidney, and lung; leukocytes also concentrate the drug. The brain and spinal cord, in contrast, contain only 10 to 30 times the amount present in plasma. Chloroquine undergoes appreciable degradation in the body. The main metabolite is desethylchloroquine, which accounts for one fourth of the total material appearing in the urine;bisdesethylchloroquine, a carboxylic acid derivative, and other metabolic products as yet uncharacterized are found in small amounts. Slightly more than half of the urinary drug products can be accounted for as unchanged chloroquine. Cardiac Electrophysiology QTc interval prolongation was studied in a randomized, placebo-controlled parallel trial in 116 healthy subjects who received either chloroquine (1000 mg) alone or in combination with oral azithromycin (500 mg, 1000 mg, and 1500 mg once daily). Co-administration of azithromycin increased the QTc interval in a dose- and concentration- dependent manner. In comparison to chloroquine alone, the maximum mean (95% upper confidence bound) increases in QTcF were 5 ms, 7 (12) ms and 9 (14) ms with the co-administration of 500 mg, 1000 mg and 1500 mg azithromycin, respectively. Microbiology Mechanism of Action: Chloroquine, a 4-aminoquinoline, is an anti-protozoal agent. The precise mechanism by which chloroquine exhibits activity is not known. Chloroquine, may exert its effect against Plasmodium species by concentrating in the acid vesicles of the parasite and by inhibiting polymerization of heme. It can also inhibit certain enzymes by its interaction with DNA. Activity in Vitro and in Clinical Infections: Chloroquine is active against the erythrocytic forms of susceptible strains of Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale , and Plasmodium vivax . Chloroquine is not active against the gametocytes and the exoerythrocytic forms including the hypnozoite stage ( P. vivax and P. ovale ) of the Plasmodium parasites. In vitro studies with Chloroquine demonstrated that it is active against the trophozoites of Entamoeba histolytica. Drug Resistance: Resistance of Plasmodium parasites to chloroquine is widespread (see INDICATIONS AND USAGE , Limitations of Use in Malaria and WARNINGS ). Plasmodium parasites exhibiting reduced susceptibility to hydroxychloroquine also show reduced susceptibility to chloroquine. Patients in whom chloroquine or hydroxychloroquine have failed to prevent or cure clinical malaria or parasitemia, or patients who acquired malaria in a geographic area where chloroquine resistance is known to occur should be treated with another form of antimalarial therapy (see WARNINGS and INDICATIONS AND USAGE , Limitations of Use)."],"indications_and_usage":["INDICATIONS AND USAGE Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale, and P.vivax . Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets is widespread in P. falciparum, and is reported in P.vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P.vivax and P.ovale (see DOSAGE AND ADMINISTRATION )."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION The dosage of chloroquine phosphate is often expressed in terms of equivalent chloroquine base. Each 500 mg tablet of Chloroquine phosphate contains the equivalent of 300 mg chloroquine base. In infants and children the dosage is preferably calculated by body weight. Prophylaxis against chloroquine-sensitive Plasmodium species Adult Dose: The dosage for prophylaxis is 500 mg (= 300 mg base) administered once per week on exactly the same day of each week. Pediatric Dose : The dosage for prophylaxis is 5 mg calculated as base, per kg of body weight, administered once per week on exactly the same day of each week. The pediatric dose should never exceed the adult dose regardless of weight. If circumstances permit, suppressive therapy should begin two weeks prior to exposure. However, failing this in adults, an initial double (loading) dose of 1 g (= 600 mg base), or in children 10 mg base/kg may be taken in two divided doses, six hours apart. The suppressive therapy should be continued for eight weeks after leaving the endemic area. Treatment of uncomplicated malaria due to chloroquine-sensitive Plasmodium species Adults : An initial dose of 1 g salt (= 600 mg base) followed by an additional 500 mg (= 300 mg base) after six to eight hours and a single dose of 500 mg (= 300 mg base) on each of two consecutive days. This represents a total dose of 2.5 g chloroquine phosphate or 1.5 g base in three days. Infants and Children: In infants and children, the recommended dose is 10 mg base/kg followed by 5 mg based/kg at 6, 24 and 36 hours (total dose 25 mg based/kg). The pediatric dose should never exceed the adult dose regardless of weight. The dosage for adults of low body weight and for infants and children should be determined as follows: First dose: 10 mg base per kg (but not exceeding a single dose of 600 mg base). Second dose: (6 hours after first dose) 5 mg base per kg (but not exceeding a single dose of 300 mg base). Third dose: (24 hours after first dose) 5 mg base per kg. Fourth dose: (36 hours after first dose) 5 mg base per kg. P. vivax and P. ovale : Concomitant therapy with an 8-aminoquinoline compound is necessary for treatment of the hypnozoite liver stage forms of the parasites. Extraintestinal Amebiasis: Adults Dosage: 1 g salt (600 mg base) daily for two days, followed by 500 mg (300 mg base) daily for at least two to three weeks. Treatment is usually combined with an effective intestinal amebicide. Geriatric Use See PRECAUTION S, Geriatric Use."],"spl_product_data_elements":["Chloroquine Phosphate Chloroquine Phosphate CHLOROQUINE PHOSPHATE CHLOROQUINE SILICON DIOXIDE ANHYDROUS DIBASIC CALCIUM PHOSPHATE HYPROMELLOSES MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE POLYETHYLENE GLYCOL POLYSORBATE 80 STARCH, CORN SODIUM STARCH GLYCOLATE TYPE A POTATO TITANIUM DIOXIDE White ROUND CN500"],"package_label_principal_display_panel":["———PRINCIPAL DISPLAY PANEL——— Rising ® NDC 64980-178-02 Chloroquine Phosphate Tablets, USP 500 mg * For use in Malaria and Extraintestinal Amebiasis Only 25 Tablets Rx Only Chloroquine-Phosphate-Tablets-USP-500-mg-25-ct"]},"tags":[{"label":"Antimalarial","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sigma non-opioid intracellular receptor 1","category":"target"},{"label":"SIGMAR1","category":"gene"},{"label":"MTOR","category":"gene"},{"label":"TMEM97","category":"gene"},{"label":"P01BA01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Discoid lupus erythematosus","category":"indication"},{"label":"Falciparum malaria","category":"indication"},{"label":"Malaria Prevention","category":"indication"},{"label":"Ovale malaria","category":"indication"},{"label":"Plasmodium Falciparum Malaria Prevention","category":"indication"},{"label":"Plasmodium Malariae Malaria Prevention","category":"indication"},{"label":"Sanofi Aventis Us","category":"company"},{"label":"Approved 1940s","category":"decade"},{"label":"Amebicides","category":"pharmacology"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anthelmintics","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antimalarials","category":"pharmacology"},{"label":"Antinematodal Agents","category":"pharmacology"},{"label":"Antiparasitic Agents","category":"pharmacology"},{"label":"Antiprotozoal Agents","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Filaricides","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"63 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"49 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"48 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"41 reports"},{"date":"","signal":"HYPERTENSION","source":"FDA FAERS","actionTaken":"41 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"40 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"40 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"37 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"37 reports"},{"date":"","signal":"TOXICITY TO VARIOUS AGENTS","source":"FDA FAERS","actionTaken":"36 reports"}],"drugInteractions":[{"url":"/drug/high-risk-qt-prolonging-agents","drug":"High Risk QT Prolonging Agents","action":"Avoid combination","effect":"Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents","source":"DrugCentral","drugSlug":"high-risk-qt-prolonging-agents"},{"url":"/drug/azithromycin","drug":"azithromycin","action":"Monitor closely","effect":"May interact with Azithromycin","source":"DrugCentral","drugSlug":"azithromycin"},{"url":"/drug/ciclosporin","drug":"ciclosporin","action":"Monitor closely","effect":"May interact with Cyclosporine","source":"DrugCentral","drugSlug":"ciclosporin"},{"url":"/drug/cimetidine","drug":"cimetidine","action":"Monitor closely","effect":"May interact with Cimetidine","source":"DrugCentral","drugSlug":"cimetidine"},{"url":"/drug/clarithromycin","drug":"clarithromycin","action":"Monitor closely","effect":"May interact with Clarithromycin","source":"DrugCentral","drugSlug":"clarithromycin"},{"url":"/drug/erythromycin","drug":"erythromycin","action":"Monitor closely","effect":"May interact with Erythromycin","source":"DrugCentral","drugSlug":"erythromycin"},{"url":"/drug/praziquantel","drug":"praziquantel","action":"Monitor closely","effect":"May interact with Praziquantel","source":"DrugCentral","drugSlug":"praziquantel"}],"commonSideEffects":[{"effect":"Hepatitis","drugRate":"reported","severity":"unknown"},{"effect":"Pancytopenia","drugRate":"reported","severity":"unknown"},{"effect":"Aplastic anemia","drugRate":"reported","severity":"unknown"},{"effect":"Reversible agranulocytosis","drugRate":"reported","severity":"unknown"},{"effect":"Thrombocytopenia","drugRate":"reported","severity":"unknown"},{"effect":"Neutropenia","drugRate":"reported","severity":"unknown"},{"effect":"Hemolytic anemia","drugRate":"reported","severity":"unknown"},{"effect":"Cardiomyopathy","drugRate":"reported","severity":"unknown"},{"effect":"Cardiac arrhythmias","drugRate":"reported","severity":"unknown"},{"effect":"Conduction disorders","drugRate":"reported","severity":"unknown"},{"effect":"QT interval prolongation","drugRate":"reported","severity":"unknown"},{"effect":"Torsade de pointes","drugRate":"reported","severity":"unknown"},{"effect":"Ventricular tachycardia","drugRate":"reported","severity":"unknown"},{"effect":"Ventricular fibrillation","drugRate":"reported","severity":"unknown"},{"effect":"Maculopathy","drugRate":"reported","severity":"unknown"},{"effect":"Macular degeneration","drugRate":"reported","severity":"unknown"},{"effect":"Irreversible retinopathy","drugRate":"reported","severity":"unknown"},{"effect":"Visual disturbances","drugRate":"reported","severity":"unknown"},{"effect":"Blurring of vision","drugRate":"reported","severity":"unknown"},{"effect":"Difficulty of focusing or accommodation","drugRate":"reported","severity":"unknown"},{"effect":"Nyctalopia","drugRate":"reported","severity":"unknown"},{"effect":"Scotomatous vision","drugRate":"reported","severity":"unknown"},{"effect":"Reversible corneal opacities","drugRate":"reported","severity":"unknown"},{"effect":"Sensorimotor disorders","drugRate":"reported","severity":"unknown"},{"effect":"Skeletal muscle myopathy","drugRate":"reported","severity":"unknown"},{"effect":"Neuropsychiatric changes","drugRate":"reported","severity":"unknown"},{"effect":"Convulsions","drugRate":"reported","severity":"unknown"},{"effect":"Mild and transient headache","drugRate":"reported","severity":"unknown"},{"effect":"Polyneuropathy","drugRate":"reported","severity":"unknown"},{"effect":"Acute extrapyramidal disorders","drugRate":"reported","severity":"unknown"}],"contraindications":["Alcoholism","Anemia","Anemia due to enzyme deficiency","Deficiency of glucose-6-phosphate dehydrogenase","Disease of liver","Disorder of eye","Disorder of macula of retina","Hearing disorder","Leukopenia","Neutropenic disorder","Porphyria","Psoriasis","Retinal disorder","Seizure disorder","Visual field defect","Visual impairment"],"specialPopulations":{"Pregnancy":"See WARNINGS, Usage in Pregnancy.","Geriatric use":"Clinical studies of chloroquine phosphate tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be used with caution in patients with hepatic impairment.","Paediatric use":"See WARNINGS and DOSAGE AND ADMINISTRATION.","Renal impairment":"the risk of toxic reactions to this drug may be greater in patients with impaired renal function.","Hepatic impairment":"it may be used with caution in patients with hepatic impairment."}},"trials":[],"aliases":[],"company":"Sanofi","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CHLOROQUINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:18:11.844408+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:18:18.332717+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:18:10.475547+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CHLOROQUINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:18:19.161562+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:18:08.947343+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:18:08.947444+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:18:20.641053+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL76/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:18:19.622002+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA090612","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:18:08.947471+00:00"}},"allNames":"aralen","offLabel":[],"synonyms":["chloroquine sulfate","chloroquine","chloroquine phosphate","chloraquine","chlorochin","chloroquine hydrochloride","chloroquine diphosphate","chloroquine HCl","chloroquine sulphate"],"timeline":[{"date":"1949-10-31","type":"positive","source":"DrugCentral","milestone":"FDA approval (Sanofi Aventis Us)"}],"aiSummary":"Aralen (Chloroquine) is a small molecule antimalarial medication originally developed by Sanofi-Aventis US and currently owned by the same company. It targets the Sigma non-opioid intracellular receptor 1 and has been FDA-approved since 1949 for various malaria-related conditions. Aralen is off-patent and has no active Orange Book patents, allowing for generic manufacturing. It has a long half-life of 570 hours and high bioavailability of 80%. As an off-patent medication, it is available from generic manufacturers.","approvals":[{"date":"1949-10-31","orphan":false,"company":"SANOFI AVENTIS US","regulator":"FDA"}],"brandName":"Aralen","ecosystem":[{"indication":"Discoid lupus erythematosus","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone benzoate","slug":"betamethasone-benzoate","company":"Parke Davis"}],"globalPrevalence":2400000},{"indication":"Falciparum malaria","otherDrugs":[{"name":"artesunate","slug":"artesunate","company":"Amivas"},{"name":"atovaquone","slug":"atovaquone","company":""},{"name":"halofantrine","slug":"halofantrine","company":"Glaxosmithkline"},{"name":"hydroxychloroquine","slug":"hydroxychloroquine","company":"Sanofi Aventis Us"}],"globalPrevalence":240000},{"indication":"Malaria Prevention","otherDrugs":[{"name":"hydroxychloroquine","slug":"hydroxychloroquine","company":"Sanofi Aventis Us"}],"globalPrevalence":240000},{"indication":"Ovale malaria","otherDrugs":[{"name":"hydroxychloroquine","slug":"hydroxychloroquine","company":"Sanofi Aventis Us"}],"globalPrevalence":240000},{"indication":"Plasmodium Falciparum Malaria Prevention","otherDrugs":[{"name":"atovaquone","slug":"atovaquone","company":""},{"name":"hydroxychloroquine","slug":"hydroxychloroquine","company":"Sanofi Aventis Us"},{"name":"proguanil","slug":"proguanil","company":"Glaxosmithkline"}],"globalPrevalence":240000},{"indication":"Plasmodium Malariae Malaria Prevention","otherDrugs":[{"name":"hydroxychloroquine","slug":"hydroxychloroquine","company":"Sanofi Aventis Us"}],"globalPrevalence":240000},{"indication":"Plasmodium Ovale Malaria Prevention","otherDrugs":[{"name":"hydroxychloroquine","slug":"hydroxychloroquine","company":"Sanofi Aventis Us"}],"globalPrevalence":240000},{"indication":"Quartan malaria","otherDrugs":[{"name":"hydroxychloroquine","slug":"hydroxychloroquine","company":"Sanofi Aventis Us"}],"globalPrevalence":240000}],"mechanism":{"target":"Sigma non-opioid intracellular receptor 1","novelty":"First-in-class","targets":[{"gene":"SIGMAR1","source":"DrugCentral","target":"Sigma non-opioid intracellular receptor 1","protein":"Sigma non-opioid intracellular receptor 1"},{"gene":"MTOR","source":"DrugCentral","target":"Serine/threonine-protein kinase mTOR","protein":"Serine/threonine-protein kinase mTOR"},{"gene":"TMEM97","source":"DrugCentral","target":"Transmembrane protein 97","protein":"Transmembrane protein 97"},{"gene":"NQO2","source":"DrugCentral","target":"Ribosyldihydronicotinamide dehydrogenase [quinone]","protein":"Ribosyldihydronicotinamide dehydrogenase [quinone]"},{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2"},{"gene":"CHRM3","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M3","protein":"Muscarinic acetylcholine receptor M3"},{"gene":"PRNP","source":"DrugCentral","target":"Major prion protein","protein":"Major prion protein"},{"gene":"ADRA2A","source":"DrugCentral","target":"Alpha-2A adrenergic receptor","protein":"Alpha-2A adrenergic receptor"},{"gene":"CHRM2","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M2","protein":"Muscarinic acetylcholine receptor M2"},{"gene":"CHRM4","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M4","protein":"Muscarinic acetylcholine receptor M4"}],"modality":"Small Molecule","drugClass":"Antimalarial","explanation":"Mechanism of Action: Chloroquine, 4-aminoquinoline, is an anti-protozoal agent. The precise mechanism by which chloroquine exhibits activity is not known. Chloroquine, may exert its effect against Plasmodium species by concentrating in the acid vesicles of the parasite and by inhibiting polymerization of heme. It can also inhibit certain enzymes by its interaction with DNA. Activity in Vitro and in Clinical Infections: Chloroquine is active against the erythrocytic forms of susceptible strains of Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax. Chloroquine is not active against the gametocytes and the exoerythrocytic forms including the hypnozoite stage (P. vivax and P. ovale) of the Plasmodium parasites. In vitro studies with Chloroquine demonstrated that it is active against the trophozoites of Entamoeba histolytica. Drug Resistance: Resistance of Plasmodium parasites to chloroquine is widespread (see INDICATIONS AND USAGE, Limitations of Use in Mal","oneSentence":"Aralen works by accumulating in the acidic compartments of the malaria parasite, disrupting its metabolism and ultimately leading to its death.","technicalDetail":"Aralen (Chloroquine) acts by accumulating in the acidic compartments of the malaria parasite, such as the food vacuole, where it inhibits the parasite's heme detoxification pathway, leading to the accumulation of toxic heme and ultimately causing parasite death.","_target_confidence":0.5},"commercial":{"launchDate":"1949","_launchSource":"DrugCentral (FDA 1949-10-31, SANOFI AVENTIS US)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/607","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CHLOROQUINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CHLOROQUINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T09:33:58.992216","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:18:24.785024+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"hydroxychloroquine","drugSlug":"hydroxychloroquine","fdaApproval":"1955-04-18","genericCount":15,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"primaquine","drugSlug":"primaquine","fdaApproval":"1952-01-23","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"amodiaquine","drugSlug":"amodiaquine","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"tafenoquine","drugSlug":"tafenoquine","fdaApproval":"2018-07-20","patentExpiry":"Dec 2, 2035","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"chloroquine","indications":{"approved":[{"name":"Discoid lupus erythematosus","source":"DrugCentral","snomedId":200938002,"regulator":"FDA","eligibility":null,"prevalenceClass":"1-5 / 10 000","globalPrevalence":2400000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (ORPHANET)"},{"name":"Falciparum malaria","source":"DrugCentral","snomedId":62676009,"regulator":"FDA","eligibility":null,"prevalenceClass":"1-9 / 100 000","globalPrevalence":240000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (European Medicines Agency2015[INST])"},{"name":"Malaria Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and children of all ages in geographic areas where resistance to chloroquine is not present.","prevalenceClass":"1-9 / 100 000","globalPrevalence":240000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (European Medicines Agency2015[INST])"},{"name":"Ovale malaria","source":"DrugCentral","snomedId":19341001,"regulator":"FDA","eligibility":null,"prevalenceClass":"1-9 / 100 000","globalPrevalence":240000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (European Medicines Agency2015[INST])"},{"name":"Plasmodium Falciparum Malaria Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and children of all ages in geographic areas where resistance to chloroquine is not present.","usPrevalence":null,"globalPrevalence":240000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency2015[INST])"},{"name":"Plasmodium Malariae Malaria Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and children of all ages in geographic areas where resistance to chloroquine is not present.","usPrevalence":null,"globalPrevalence":240000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency2015[INST])"},{"name":"Plasmodium Ovale Malaria Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults and children of all ages in geographic areas where resistance to chloroquine is not present.","usPrevalence":null,"globalPrevalence":240000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency2015[INST])"},{"name":"Quartan malaria","source":"DrugCentral","snomedId":27618009,"regulator":"FDA","eligibility":null,"prevalenceClass":"1-9 / 100 000","globalPrevalence":240000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (European Medicines Agency2015[INST])"},{"name":"Rheumatoid arthritis","source":"DrugCentral","snomedId":69896004,"regulator":"FDA","eligibility":null,"usPrevalence":1500000,"globalPrevalence":18000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"},{"name":"Systemic lupus erythematosus","source":"DrugCentral","snomedId":55464009,"regulator":"FDA","eligibility":null,"prevalenceClass":"1-5 / 10 000","globalPrevalence":3496000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (36241363[PMID])"},{"name":"Vivax malaria","source":"DrugCentral","snomedId":27052006,"regulator":"FDA","prevalenceClass":"1-9 / 100 000","globalPrevalence":240000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (European Medicines Agency2015[INST])"}],"offLabel":[{"name":"Coronavirus infection","source":"DrugCentral","drugName":"CHLOROQUINE","evidenceCount":2333,"evidenceLevel":"strong"},{"name":"Hypercalcemia associated with Sarcoidosis","source":"DrugCentral","drugName":"CHLOROQUINE","evidenceCount":10,"evidenceLevel":"emerging"},{"name":"Juvenile rheumatoid arthritis","source":"DrugCentral","drugName":"CHLOROQUINE","evidenceCount":111,"evidenceLevel":"strong"},{"name":"Polymorphic light eruption","source":"DrugCentral","drugName":"CHLOROQUINE","evidenceCount":11,"evidenceLevel":"moderate"},{"name":"Porphyria cutanea tarda","source":"DrugCentral","drugName":"CHLOROQUINE","evidenceCount":172,"evidenceLevel":"strong"},{"name":"Q fever endocarditis","source":"DrugCentral","drugName":"CHLOROQUINE","evidenceCount":38,"evidenceLevel":"moderate"},{"name":"Vasculitis of the skin","source":"DrugCentral","drugName":"CHLOROQUINE","evidenceCount":175,"evidenceLevel":"strong"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"hydroxychloroquine","brandName":"hydroxychloroquine","genericName":"hydroxychloroquine","approvalYear":"1955","relationship":"same-class"},{"drugId":"primaquine","brandName":"primaquine","genericName":"primaquine","approvalYear":"1952","relationship":"same-class"},{"drugId":"amodiaquine","brandName":"amodiaquine","genericName":"amodiaquine","approvalYear":"","relationship":"same-class"},{"drugId":"tafenoquine","brandName":"tafenoquine","genericName":"tafenoquine","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01480154","phase":"PHASE1","title":"Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-11-23","conditions":["Advanced Malignant Solid Neoplasm","Stage III Cutaneous Melanoma AJCC v7","Stage III Prostate Cancer AJCC v7","Stage III Renal Cell Cancer AJCC v7","Stage IIIA Cutaneous Melanoma AJCC v7","Stage IIIB Cutaneous Melanoma AJCC v7","Stage IIIC Cutaneous Melanoma AJCC v7","Stage IV Cutaneous Melanoma AJCC v6 and v7","Stage IV Prostate Cancer AJCC v7","Stage IV Renal Cell Cancer AJCC v7"],"enrollment":62,"completionDate":"2026-03-19"},{"nctId":"NCT05942911","phase":"PHASE2","title":"Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Incannex Healthcare Ltd","startDate":"2023-11-22","conditions":["Rheumatoid Arthritis"],"enrollment":20,"completionDate":"2025-10-28"},{"nctId":"NCT06923592","phase":"PHASE3","title":"Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar","status":"RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2025-05-12","conditions":["Malaria Vivax","Malaria Falciparum","Plasmodium Vivax","Plasmodium Falciparum"],"enrollment":19200,"completionDate":"2027-04-28"},{"nctId":"NCT07343635","phase":"NA","title":"The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea","status":"RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2026-02-01","conditions":["Erythematotelangiectatic Rosacea"],"enrollment":186,"completionDate":"2027-07-01"},{"nctId":"NCT03822780","phase":"NA","title":"Hydroxychloroquin (HCQ) in chILD of Genetic Defect","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2017-07-01","conditions":["Surfactant Dysfunction"],"enrollment":25,"completionDate":"2026-03-15"},{"nctId":"NCT04532346","phase":"EARLY_PHASE1","title":"Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2024-09-01","conditions":["Interstitial Lung Disease","Surfactant Dysfunction"],"enrollment":60,"completionDate":"2027-04"},{"nctId":"NCT07467252","phase":"PHASE2","title":"AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT","status":"NOT_YET_RECRUITING","sponsor":"Ministry of Health, Saudi Arabia","startDate":"2026-09","conditions":["Pulmonary Tuberculosis"],"enrollment":200,"completionDate":"2028-06"},{"nctId":"NCT04527549","phase":"PHASE2","title":"Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-06-01","conditions":["Clinical Stage IV Cutaneous Melanoma AJCC v8","Locally Advanced Melanoma","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Melanoma AJCC v8","Unresectable Melanoma"],"enrollment":5,"completionDate":"2024-01-08"},{"nctId":"NCT05016297","phase":"PHASE2","title":"Efficacy and Safety of Baricitinib in Sjogren's Syndrome","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2022-07-14","conditions":["Sjogren's Syndrome"],"enrollment":87,"completionDate":"2024-11-22"},{"nctId":"NCT07443436","phase":"PHASE2","title":"Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-10-01","conditions":["Interstitial Lung Disease"],"enrollment":30,"completionDate":"2027-10-01"},{"nctId":"NCT07430592","phase":"PHASE2","title":"This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria","status":"NOT_YET_RECRUITING","sponsor":"R. Kiplin Guy","startDate":"2026-03-20","conditions":["Malaria","Malaria Vivax","Radical Cure"],"enrollment":104,"completionDate":"2028-11-20"},{"nctId":"NCT07436104","phase":"PHASE4","title":"Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat.","status":"COMPLETED","sponsor":"MAHAN Trust","startDate":"2004-01-01","conditions":["Hypertension (HTN)","Diarrhea","Pneumonia","Malaria Fever","COPD","Asthma (Diagnosis)","Diarrhea Chronic"],"enrollment":72564,"completionDate":"2023-08-31"},{"nctId":"NCT05799378","phase":"PHASE3","title":"Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2024-06-27","conditions":["Systemic Lupus Erythematosus"],"enrollment":330,"completionDate":"2029-06-30"},{"nctId":"NCT05041907","phase":"PHASE2","title":"Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2021-09-30","conditions":["COVID-19"],"enrollment":3800,"completionDate":"2027-01"},{"nctId":"NCT04345692","phase":"PHASE3","title":"A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients","status":"TERMINATED","sponsor":"Queen's Medical Center","startDate":"2020-03-26","conditions":["COVID-19"],"enrollment":17,"completionDate":"2020-08-31"},{"nctId":"NCT02595346","phase":"PHASE2","title":"Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2016-05-17","conditions":["Antiphospholipid Syndrome (APS)"],"enrollment":25,"completionDate":"2020-08-05"},{"nctId":"NCT06408298","phase":"EARLY_PHASE1","title":"HCQ in Resectable Localized Prostate Cancer","status":"RECRUITING","sponsor":"Lionel.D.Lewis, MD","startDate":"2026-01-06","conditions":["Resectable Localized Prostate Cancer"],"enrollment":20,"completionDate":"2029-03"},{"nctId":"NCT03598595","phase":"PHASE1,PHASE2","title":"Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-28","conditions":["Recurrent Osteosarcoma","Refractory Osteosarcoma"],"enrollment":31,"completionDate":"2026-05-31"},{"nctId":"NCT04201457","phase":"PHASE1,PHASE2","title":"A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2020-01-17","conditions":["Low Grade Glioma (LGG) of Brain With BRAF Aberration","High Grade Glioma (HGG) of the Brain With BRAF Aberration","Low Grade Glioma of Brain With Neurofibromatosis Type 1"],"enrollment":57,"completionDate":"2026-03-31"},{"nctId":"NCT04524702","phase":"PHASE2","title":"Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2020-09-14","conditions":["Advanced Pancreatic Adenocarcinoma","Metastatic Pancreatic Adenocarcinoma","Stage IV Pancreatic Cancer AJCC v8"],"enrollment":10,"completionDate":"2023-06-06"},{"nctId":"NCT05842174","phase":"PHASE1,PHASE2","title":"Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-02-01","conditions":["Hepatocellular Carcinoma"],"enrollment":93,"completionDate":"2030-10-15"},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":["Psoriasis","Atopic Dermatitis"],"enrollment":10,"completionDate":"2030-06-01"},{"nctId":"NCT06076837","phase":"PHASE1","title":"The Seven Trial: Exploiting the Unfolded Protein Response","status":"ACTIVE_NOT_RECRUITING","sponsor":"HonorHealth Research Institute","startDate":"2025-01-09","conditions":["Pancreatic Cancer Metastatic","Pancreatic Adenocarcinoma Metastatic"],"enrollment":6,"completionDate":"2026-12"},{"nctId":"NCT04481633","phase":"NA","title":"Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2020-09-09","conditions":["COVID-19"],"enrollment":552,"completionDate":"2022-12-06"},{"nctId":"NCT06575647","phase":"PHASE4","title":"Vivax Elimination With Tafenoquine (VET) Study","status":"COMPLETED","sponsor":"Shoklo Malaria Research Unit","startDate":"2025-02-19","conditions":["Malaria","Malaria, Vivax","Plasmodium Vivax","Plasmodium Vivax Malaria"],"enrollment":1242,"completionDate":"2025-10-04"},{"nctId":"NCT06776445","phase":"PHASE1","title":"Efficacy and Safety of Different Dose Regimens of Gabapentin for Treating Erythema/Flushing in Rosacea: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2024-01-05","conditions":["Rosacea","Rosacea Subtype 1 (Erythematotelangiectatic)"],"enrollment":50,"completionDate":"2025-07-31"},{"nctId":"NCT06971744","phase":"PHASE2","title":"Autophagy Maintenance (AUTOMAIN)","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2025-12-18","conditions":["Ovarian Cancer"],"enrollment":38,"completionDate":"2029-06-18"},{"nctId":"NCT05843188","phase":"PHASE2","title":"Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-08-09","conditions":["Metastatic Colorectal Cancer"],"enrollment":155,"completionDate":"2026-10-24"},{"nctId":"NCT02615938","phase":"PHASE2","title":"Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD)","status":"TERMINATED","sponsor":"Matthias Griese","startDate":"2015-08-21","conditions":["Interstitial Lung Disease","Diffuse Parenchymal Lung Disease","Children´s Interstitial Lung Disease"],"enrollment":35,"completionDate":"2020-09-09"},{"nctId":"NCT04344379","phase":"PHASE3","title":"Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-17","conditions":["SARS-CoV-2 Infection"],"enrollment":122,"completionDate":"2020-06-18"},{"nctId":"NCT06083688","phase":"PHASE4","title":"Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi","status":"ACTIVE_NOT_RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2024-10-14","conditions":["Malaria,Falciparum","Anemia in Children"],"enrollment":1000,"completionDate":"2026-01"},{"nctId":"NCT07230028","phase":"PHASE4","title":"Doxycycline Boosted Therapy in Lyme Borreliosis: DoBo Study.","status":"NOT_YET_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2026-03-01","conditions":["Lyme Borreliosis, Nervous System"],"enrollment":50,"completionDate":"2027-11-01"},{"nctId":"NCT05690841","phase":"PHASE3","title":"FocaL Mass Drug Administration for Vivax Malaria Elimination","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-10-14","conditions":["Plasmodium Vivax Malaria","Malaria"],"enrollment":7530,"completionDate":"2027-05-01"},{"nctId":"NCT04132505","phase":"PHASE1","title":"Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-22","conditions":["Metastatic Pancreatic Adenocarcinoma","Stage IV Pancreatic Cancer AJCC v8"],"enrollment":39,"completionDate":"2026-12-31"},{"nctId":"NCT04787991","phase":"PHASE1","title":"Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Cancer Insight, LLC","startDate":"2021-08-09","conditions":["Metastatic Pancreatic Adenocarcinoma"],"enrollment":45,"completionDate":"2025-07-31"},{"nctId":"NCT05576896","phase":"PHASE2","title":"Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2022-10-10","conditions":["Stage IV Colorectal Cancer Positive for BRAF V600E Mutation","Colorectal Cancer","Colorectal Cancer Stage IV"],"enrollment":43,"completionDate":"2028-07-01"},{"nctId":"NCT00977470","phase":"PHASE2","title":"Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2009-10","conditions":["Non-small Cell Lung Cancer"],"enrollment":76,"completionDate":"2027-12"},{"nctId":"NCT05036226","phase":"PHASE1,PHASE2","title":"COAST Therapy in Advanced Solid Tumors and Prostate Cancer","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2022-03-03","conditions":["Prostate Cancer Recurrent","Solid Tumor, Adult"],"enrollment":76,"completionDate":"2027-05-21"},{"nctId":"NCT07190534","phase":"","title":"The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)","status":"NOT_YET_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2025-11","conditions":["Frontal Fibrosing Alopecia","Cicatricial Alopecia"],"enrollment":50,"completionDate":"2027-05"},{"nctId":"NCT04007562","phase":"","title":"Acute Rhabdomyolysis and Muscle Pain Associated With Mutations in the LPIN1 Gene - A Retrospective Study Describing the Safety and Efficacy of Hydroxychloroquine Sulfate Given on a Compassionate Basis to Patients Suffering From Lipin-1 Deficiency","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-11-04","conditions":["LIPIN1 Deficiency"],"enrollment":0,"completionDate":"2019-11-04"},{"nctId":"NCT05221320","phase":"PHASE2","title":"Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies","status":"TERMINATED","sponsor":"BioMed Valley Discoveries, Inc","startDate":"2022-05-26","conditions":["Tumor, Solid","Gastrointestinal Cancer"],"enrollment":47,"completionDate":"2024-07-14"},{"nctId":"NCT04333654","phase":"PHASE1","title":"Hydroxychloroquine in Outpatient Adults With COVID-19","status":"TERMINATED","sponsor":"Sanofi","startDate":"2020-04-12","conditions":["Coronavirus Infection"],"enrollment":8,"completionDate":"2020-05-26"},{"nctId":"NCT06652113","phase":"NA","title":"Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-11-15","conditions":["Recurrent Pregnancy Loss","Euthyroid With Thyroid Antibodies"],"enrollment":796,"completionDate":"2037-03"},{"nctId":"NCT03030118","phase":"PHASE2","title":"Study of Anti-Malarials in Incomplete Lupus Erythematosus","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2017-12-28","conditions":["Systemic Lupus Erythematosus"],"enrollment":187,"completionDate":"2024-06-30"},{"nctId":"NCT05841758","phase":"PHASE4","title":"Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-07-30","conditions":["Sarcoidosis, Pulmonary"],"enrollment":140,"completionDate":"2029-07-01"},{"nctId":"NCT04397328","phase":"PHASE3","title":"COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada","status":"WITHDRAWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2020-05-30","conditions":["COVID-19"],"enrollment":0,"completionDate":"2021-04-30"},{"nctId":"NCT03037437","phase":"PHASE2","title":"Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-02-16","conditions":["Hepatocellular Cancer"],"enrollment":64,"completionDate":"2025-06-27"},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":["Rheumatic Disease"],"enrollment":80,"completionDate":"2027-09"},{"nctId":"NCT04669197","phase":"PHASE2","title":"Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"HonorHealth Research Institute","startDate":"2020-12-01","conditions":["Untreated Resectable Pancreatic Adenocarcinoma","Borderline Resectable Pancreatic Adenocarcinoma","Locally Advanced Pancreatic Adenocarcinoma"],"enrollment":19,"completionDate":"2025-12-30"},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":["Rheumatoid Arthritis"],"enrollment":400,"completionDate":"2029-03"},{"nctId":"NCT06666491","phase":"PHASE3","title":"An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":["Malaria, Vivax"],"enrollment":300,"completionDate":"2026-05-25"},{"nctId":"NCT04532931","phase":"PHASE2","title":"Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-09-03","conditions":["COVID-19"],"enrollment":192,"completionDate":"2021-08-23"},{"nctId":"NCT01506973","phase":"PHASE1,PHASE2","title":"A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2011-12","conditions":["Advanced Adenocarcinoma","Metastatic Adenocarcinoma"],"enrollment":119,"completionDate":"2022-03"},{"nctId":"NCT05540470","phase":"NA","title":"Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield","status":"COMPLETED","sponsor":"Centre Hospitalier de Cayenne","startDate":"2022-09-12","conditions":["Malaria, Vivax"],"enrollment":1991,"completionDate":"2025-04-25"},{"nctId":"NCT03377179","phase":"PHASE2","title":"A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2018-03-07","conditions":["Cholangiocarcinoma","Cholangiocarcinoma Non-resectable","Cholangiocarcinoma, Perihilar","Cholangiocarcinoma, Extrahepatic","Cholangiocarcinoma, Intrahepatic"],"enrollment":65,"completionDate":"2022-06-21"},{"nctId":"NCT03032406","phase":"PHASE2","title":"CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2017-01-23","conditions":["Breast Cancer Stage IIB"],"enrollment":53,"completionDate":"2026-01-01"},{"nctId":"NCT06676384","phase":"PHASE4","title":"Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?","status":"RECRUITING","sponsor":"Christian Medical College, Vellore, India","startDate":"2025-02-15","conditions":["IgA Nephropathy","Renal Insufficiency, Chronic","IgA Vasculitis","IGA Glomerulonephritis"],"enrollment":585,"completionDate":"2029-08"},{"nctId":"NCT07061717","phase":"PHASE3","title":"Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-07-01","conditions":["Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer"],"enrollment":474,"completionDate":"2029-07-01"},{"nctId":"NCT04464759","phase":"PHASE1,PHASE2","title":"A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma","status":"RECRUITING","sponsor":"Ravi Amaravadi, MD","startDate":"2020-10-21","conditions":["Melanoma"],"enrollment":94,"completionDate":"2025-10-30"},{"nctId":"NCT04354649","phase":"PHASE2","title":"Immune-Mediated Pathophysiology And Clinical Triage Program","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2021-09-16","conditions":["Arthritis","Arthralgia"],"enrollment":46,"completionDate":"2029-07"},{"nctId":"NCT02603146","phase":"PHASE2","title":"Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-04-27","conditions":["Healthy Participants","Rheumatoid Arthritis (RA) Prevention"],"enrollment":144,"completionDate":"2022-11-01"},{"nctId":"NCT06319560","phase":"NA","title":"Hydroxychloroquine in Type 2 Diabetes During Pregnancy","status":"RECRUITING","sponsor":"National University of Malaysia","startDate":"2024-03-24","conditions":["Diabetes in Pregnancy","Type 2 Diabetes"],"enrollment":56,"completionDate":"2027-01-01"},{"nctId":"NCT04335084","phase":"PHASE2","title":"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","status":"COMPLETED","sponsor":"ProgenaBiome","startDate":"2020-06-22","conditions":["COVID-19","Coronavirus Infection","Sars-CoV2","Corona Virus Infection","COVID","Coronavirus","Coronavirus-19","Coronavirus 19"],"enrollment":254,"completionDate":"2024-04-11"},{"nctId":"NCT06350630","phase":"PHASE2","title":"Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2025-06","conditions":["IgA Nephropathy"],"enrollment":334,"completionDate":"2030-12-31"},{"nctId":"NCT03979651","phase":"NA","title":"MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2019-10-15","conditions":["Metastatic NRAS Melanoma"],"enrollment":29,"completionDate":"2023-01-03"},{"nctId":"NCT05788094","phase":"PHASE4","title":"ACT vs CQ With Tafenoquine for P. Vivax Mono-infection","status":"RECRUITING","sponsor":"Shoklo Malaria Research Unit","startDate":"2023-06-26","conditions":["Malaria","Malaria, Vivax","Plasmodium Vivax Malaria"],"enrollment":606,"completionDate":"2026-08-31"},{"nctId":"NCT04379492","phase":"PHASE2","title":"A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19","status":"WITHDRAWN","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-05-05","conditions":["COVID-19","COVID19","Sars-CoV2","SARS-Cov-2"],"enrollment":0,"completionDate":"2020-09-25"},{"nctId":"NCT06939582","phase":"PHASE1,PHASE2","title":"Hydroxychloroquine Sulfate Tablets for Radiation-induced Oral Mucositis","status":"RECRUITING","sponsor":"Xingchen Peng","startDate":"2024-12-22","conditions":["Radiation-induced Oral Mucositis"],"enrollment":158,"completionDate":"2025-06-20"},{"nctId":"NCT06020378","phase":"","title":"Hydroxychloroquine May be Beneficial for Preeclampsia","status":"ACTIVE_NOT_RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-01-01","conditions":["Pre-Eclampsia"],"enrollment":462,"completionDate":"2026-12-01"},{"nctId":"NCT05630989","phase":"","title":"A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy","status":"RECRUITING","sponsor":"Mandana Kamgar, MD","startDate":"2023-02-07","conditions":["Pancreatic Ductal Adenocarcinoma"],"enrollment":80,"completionDate":"2027-08-01"},{"nctId":"NCT05365893","phase":"EARLY_PHASE1","title":"PHL Treatment in Pancreatic Cancer","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2021-10-20","conditions":["Pancreatic Ductal Adenocarcinoma"],"enrollment":20,"completionDate":"2026-12-31"},{"nctId":"NCT03825289","phase":"PHASE1","title":"Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2019-01-18","conditions":["Metastatic Pancreatic Carcinoma","Stage II Pancreatic Cancer","Stage IIA Pancreatic Cancer","Stage IIB Pancreatic Cancer","Stage III Pancreatic Cancer","Stage IV Pancreatic Cancer","Unresectable Pancreatic Carcinoma"],"enrollment":25,"completionDate":"2029-03"},{"nctId":"NCT05083780","phase":"PHASE1","title":"Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changhoon Yoo","startDate":"2021-11-30","conditions":["Pancreatic Cancer"],"enrollment":40,"completionDate":"2026-12-30"},{"nctId":"NCT04011410","phase":"PHASE2","title":"Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer","status":"COMPLETED","sponsor":"Patrick Hensley","startDate":"2019-12-03","conditions":["Prostate Cancer Recurrent"],"enrollment":20,"completionDate":"2024-03-08"},{"nctId":"NCT04523857","phase":"PHASE2","title":"ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-11-01","conditions":["Breast Cancer"],"enrollment":66,"completionDate":"2028-12"},{"nctId":"NCT04735068","phase":"PHASE2","title":"Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-04-09","conditions":["Non-Small Cell Lung Cancer","KRAS Mutation-Related Tumors"],"enrollment":9,"completionDate":"2023-12-31"},{"nctId":"NCT04841148","phase":"PHASE2","title":"Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-06-01","conditions":["Breast Cancer"],"enrollment":96,"completionDate":"2028-05"},{"nctId":"NCT06862284","phase":"PHASE2","title":"Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-03-10","conditions":["Primary Sjögren's Syndrome (pSS)"],"enrollment":30,"completionDate":"2027-08-31"},{"nctId":"NCT04363827","phase":"PHASE2","title":"Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2020-05-14","conditions":["COVID19","Hydroxychloroquine","Prophylaxis","Treatment","SARS-CoV-2"],"enrollment":155,"completionDate":"2021-09-30"},{"nctId":"NCT04704999","phase":"PHASE4","title":"Southeast Asia Dose Optimization of Tafenoquine","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2024-07-22","conditions":["Plasmodium Vivax Malaria"],"enrollment":700,"completionDate":"2028-02-07"},{"nctId":"NCT00131703","phase":"PHASE3","title":"Efficacy and Safety of Sulphadoxine-pyrimethamine and Amodiaquine in Ghanaian Pregnant Women","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2003-03","conditions":["Malaria","Pregnancy"],"enrollment":900,"completionDate":"2005-03"},{"nctId":"NCT04973566","phase":"PHASE1","title":"A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-31","conditions":["Healthy"],"enrollment":48,"completionDate":"2022-05-27"},{"nctId":"NCT04349371","phase":"PHASE2","title":"Saved From COVID-19 - Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID","status":"TERMINATED","sponsor":"Columbia University","startDate":"2020-04-21","conditions":["COVID","Coronavirus Infection"],"enrollment":5,"completionDate":"2021-02-11"},{"nctId":"NCT05126147","phase":"PHASE4","title":"Hydroxychloroquine in Mild Graves' Orbitopathy","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-03-21","conditions":["Graves Ophthalmopathy"],"enrollment":108,"completionDate":"2026-12-31"},{"nctId":"NCT04911816","phase":"PHASE1,PHASE2","title":"Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"West Virginia University","startDate":"2021-07-16","conditions":["Adenocarcinoma of the Pancreas"],"enrollment":40,"completionDate":"2030-06"},{"nctId":"NCT03529396","phase":"PHASE2","title":"Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients","status":"COMPLETED","sponsor":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","startDate":"2018-07-20","conditions":["Vivax Malaria","G6PD Deficiency"],"enrollment":106,"completionDate":"2023-07-06"},{"nctId":"NCT06389201","phase":"NA","title":"Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2024-08-01","conditions":["Nasopharyngeal Carcinoma"],"enrollment":30,"completionDate":"2034-08-01"},{"nctId":"NCT03774472","phase":"PHASE1,PHASE2","title":"Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-08-20","conditions":["Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Prognostic Stage IV Breast Cancer AJCC v8"],"enrollment":15,"completionDate":"2024-04-17"},{"nctId":"NCT04386057","phase":"PHASE2","title":"LY3214996 +/- HCQ in Pancreatic Cancer","status":"COMPLETED","sponsor":"Kimberly Perez, MD","startDate":"2020-05-27","conditions":["Pancreatic Cancer","Advanced Cancer"],"enrollment":52,"completionDate":"2024-02-05"},{"nctId":"NCT05119140","phase":"PHASE1,PHASE2","title":"Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2022-06-10","conditions":["Ulcerative Colitis (Disorder)"],"enrollment":3,"completionDate":"2025-05"},{"nctId":"NCT04573153","phase":"PHASE2,PHASE3","title":"Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients","status":"TERMINATED","sponsor":"ScandiBio Therapeutics AB","startDate":"2020-09-21","conditions":["COVID-19"],"enrollment":100,"completionDate":"2022-05-05"},{"nctId":"NCT06816810","phase":"PHASE2","title":"A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2025-03","conditions":["Parkinson&Amp;#39;s Disease"],"enrollment":40,"completionDate":"2027-03"},{"nctId":"NCT03636152","phase":"PHASE2","title":"Management of Cardiovascular Disease in Kidney Disease (MaCK) Study","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2018-12-14","conditions":["Chronic Kidney Disease","Cardiovascular Disease","Inflammation","Atherosclerosis","Aortic Stiffness"],"enrollment":100,"completionDate":"2024-01-31"},{"nctId":"NCT04397679","phase":"PHASE1","title":"Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma","status":"TERMINATED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2021-08-12","conditions":["Glioblastoma","Gliosarcoma"],"enrollment":2,"completionDate":"2024-05-14"},{"nctId":"NCT06768294","phase":"PHASE2","title":"Baricitinib in CPPD - the BAPTIST Study","status":"NOT_YET_RECRUITING","sponsor":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","startDate":"2025-01","conditions":["Calcium Pyrophosphate Deposition Disease","Chondrocalcinosis"],"enrollment":32,"completionDate":"2027-01"},{"nctId":"NCT04385264","phase":"PHASE2,PHASE3","title":"#StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19","status":"WITHDRAWN","sponsor":"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland","startDate":"2022-01","conditions":["COVID-19"],"enrollment":0,"completionDate":"2022-12"},{"nctId":"NCT05287321","phase":"PHASE3","title":"The Efficacy of Aspirin Combined With Hydroxychloroquine Treatment in High Risk Pregnancies for Preeclampsia","status":"RECRUITING","sponsor":"Yoo-min Kim","startDate":"2022-05-31","conditions":["Preeclampsia"],"enrollment":58,"completionDate":"2026-12-31"},{"nctId":"NCT06739759","phase":"NA","title":"Ovarian Hyperstimulation Syndrome Prevention","status":"RECRUITING","sponsor":"Aljazeera Hospital","startDate":"2024-11-17","conditions":["Ovarian Hyper Stimulation Syndrome (OHSS)"],"enrollment":300,"completionDate":"2025-07-30"},{"nctId":"NCT04214418","phase":"PHASE1,PHASE2","title":"Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies","status":"TERMINATED","sponsor":"Columbia University","startDate":"2020-02-12","conditions":["Gastrointestinal Cancer"],"enrollment":27,"completionDate":"2022-07-01"},{"nctId":"NCT03503058","phase":"PHASE2","title":"Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria","status":"COMPLETED","sponsor":"Sanaria Inc.","startDate":"2022-05-07","conditions":["Malaria"],"enrollment":345,"completionDate":"2024-05-29"}],"whoEssential":true,"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"Chloroquine Phosphate"},{"form":"TABLET, COATED","route":"ORAL","productName":"CHLOROQUINE PHOSPHATE"},{"form":"TABLET, COATED","route":"ORAL","productName":"Chloroquine Phosphate"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Chloroquine phosphate"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"3949","NDDF":"002938","UNII":"886U3H6UFF","CHEBI":"CHEBI:3638","VANDF":"4018227","INN_ID":"386","RXNORM":"203119","UMLSCUI":"C0008269","chemblId":"CHEMBL76","ChEMBL_ID":"CHEMBL1326","KEGG_DRUG":"D02125","DRUGBANK_ID":"DB00608","PDB_CHEM_ID":" CLQ","PUBCHEM_CID":"2719","SNOMEDCT_US":"14728000","IUPHAR_LIGAND_ID":"5535","SECONDARY_CAS_RN":"132-73-0","MESH_DESCRIPTOR_UI":"D002738","MESH_SUPPLEMENTAL_RECORD_UI":"C023676"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1949-","companyName":"Sanofi","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"570.0 hours","clearance":"4.1 mL/min/kg","bioavailability":"80%","fractionUnbound":"0.43%","volumeOfDistribution":"140.0 L/kg"},"publicationCount":23185,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"P01BA01","allCodes":["P01BA01","P01BB52"]},"biosimilarFilings":[],"originalDeveloper":"Sanofi Aventis Us","recentPublications":[{"date":"2026 Mar 1","pmid":"41901254","title":"Captivating Synergistic, Dose-Dependent Anticancer Effects of Tumor-Regulation Modulators Chloroquine and Ivermectin Completely Abolished by an Opposing Modulator, Deoxycholic Acid, in Hamster Fibrosarcoma: In Vivo, In Vitro, and Literature Review.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2026 Mar 11","pmid":"41899507","title":"Triptolide Triggers Protective Autophagy via ROS Induction in NSCLC: Therapeutic Synergy with Autophagy Inhibition.","journal":"Cancers"},{"date":"2026 Mar 27","pmid":"41894411","title":"Reduced cytochrome P-450 (CYP) 2D6 activity and Plasmodium vivax malaria risk in Amazonians: A retrospective, population-based cohort study.","journal":"PLoS neglected tropical diseases"},{"date":"2026 Mar 17","pmid":"41891011","title":"Sustained High Prevalence of Multiple Antimalarial Drug Resistance Markers in Uganda in 2023-24.","journal":"medRxiv : the preprint server for health sciences"},{"date":"2026 Mar 24","pmid":"41886893","title":"Restoration of autophagy-lysosomal function via transcranial focused ultrasound stimulation ameliorates β-amyloid pathology and cognitive deficits in an Alzheimer's disease model.","journal":"Ultrasonics"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"1949","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1949-10-31T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2011-01-21T00:00:00.000Z","mah":"NATCO PHARMA LTD","brand_name_local":null,"application_number":"ANDA091621"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-04-28T00:00:00.000Z","mah":"IMPAX LABS","brand_name_local":null,"application_number":"ANDA040516"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-03-17T00:00:00.000Z","mah":"IMPAX LABS","brand_name_local":null,"application_number":"ANDA080880"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-03-10T00:00:00.000Z","mah":"SUVEN PHARMS","brand_name_local":null,"application_number":"ANDA214756"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-07-24T00:00:00.000Z","mah":"NATCO PHARMA LTD","brand_name_local":null,"application_number":"ANDA090612"},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:18:24.785024+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}